Clinical Trials Sponsored by Philip Diaz

Total 799 results

Philip Diaz

Completed

Green Tea Anticancer Mechanisms in Smokers

Cancer

United States
Philip Diaz

Completed

A Registry of COPD Patients to be Used for Future Studies

Chronic Obstructive Lung Disease

United States
Philip Diaz
National Institutes of Health (NIH)

Completed

Alveolar Macrophage Proteomics in HIV-associated Emphysema (HIVE)

HIV Infections | Emphysema | HIV

United States
Philip Diaz
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Smoking Cessation Using Motivational Therapy and Varenicline

HIV Infections | Smoking

United States
JUAN V. LOPEZ DIAZ
Omphis Foundation

Not yet recruiting

Study of Manual Therapy Plus Therapeutic Exercise in Geriatrics

Pain | Disability Physical | Aging Disorder
Sarah Diaz

Completed

Laparoscopic TAP Block for Sleeve Gastrectomy: Does Timing Matter

Obesity | Pain, Postoperative

United States
Philips Healthcare
Philips Medical Systems

Completed

Therapeutic Magnetic Resonance Imaging (MRI)-Guided High Intensity Focused Ultrasound (HIFU) Ablation of Uterine Fibroids

Uterine Fibroids

Korea, Republic of, Netherlands, France, Germany
Philips Healthcare
Philips Medical Systems

Completed

Therapeutic MRI-HIFU Ablation of Uterine Fibroids in a 3T MRI Scanner

Uterine Leiomyomas

Norway
Philip Morris Products S.A.

Recruiting

Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms.

Smoking | Tobacco Use | COPD

United States, Bulgaria, Czechia, Germany, Japan, Romania, Slovakia, United Kingdom
Philip Morris Products S.A.

Completed

Reduction of Exposure, Inflammation, and Oxidative Stress Following at Least 2 Years of Switching to THS Use Compared to Cigarette Smoking

Smoking | Inflammation | Oxidative Stress | Smoking Abstinence

Japan, Germany, Czechia, Greece
Philip Morris Products S.A.

Completed

Reduced HPHC Exposure in Cigarette Smokers Switching to P4M3 Gen. 2.0 Compared to Continuing Smoking, or Smoking Abstinence

Nicotine | Nicotine Vaping | Vaping

United Kingdom
Philip Morris Products S.A.

Terminated

Cross-Sectional Survey on the Use of Tobacco Products - Italy

Tobacco Use

Switzerland
Philip Morris Products S.A.

Active, not recruiting

Pharmacokinetics and Comparative Bioavailability of Nicotine From Two Variants of NP2, NP2-4mg and NP2-6mg, Compared to Nicotine Lozenge 4mg (Loz-4mg) and Nicotine Gum 4mg (Gum-4mg)

Tobacco Use

Canada
Philip Morris Products S.A.

Completed

Comparison of Abdominal Aortic Aneurysm Growth in Adult Smoking Patients Who Either Switch to IQOS, Continue Smoking, or Quit Smoking.

Smoking | Abdominal Aortic Aneurysm | IQOS Use

Japan
Philip Morris Products S.A.

Completed

A Smoking Cessation Study to Understand the Biological and Functional Changes After One Year of Smoking Cessation (RIBESC)

Cigarette Smoking

United States, Poland, Germany, Japan, United Kingdom
Philip Morris Products S.A.

Completed

Nicotine Pharmacokinetics and Subjective Effects of Nicotine Pouch 1.0 Compared to Velo® Ice Cool and Zyn® Cool Mint Mini Dry in Healthy Smokers

Smoking | Nicotine

United Kingdom
Philip Grant

Withdrawn

Effect of Reducing Nucleotide Exposure on Bone Health (ReNew) (ReNew)

HIV/AIDS | Osteopenia | HIV-1-infection

United States
Philip Morris Products S.A.

Completed

Product Use and Adaptation, Safety and Tolerability of P3P in Adult Healthy Smokers Switching to it

Pharmacokinetics

Russian Federation
Philip Morris Products S.A.

Completed

Nicotine Pharmacokinetic Profile of the CHTP 1.1 M

Smoking

Japan
Philip Morris Products S.A.

Completed

Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting

Smoking

Japan
Philip Morris Products S.A.

Completed

Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol).

Smoking

Japan
Philip Morris Products S.A.

Completed

Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol)

Smoking

United States
Philip Morris Products S.A.

Completed

Reduced Exposure Study in Smokers Using THS 2.2 With 5 Days in a Confinement Setting.

Smoking

Poland
Philip Morris Products S.A.

Completed

European Exposure Study

Smoking

United Kingdom
Philip Morris Products S.A.

Completed

User Acceptability of a Nicotine Lactate Delivery System (P3L)

Smoking

United States
Philip Morris Products S.A.

Unknown

Japanese Post-Market Cohort Study

Smoking | Tobacco Product

Japan
Philip Morris Products S.A.

Completed

Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)

Smoking

Japan
Philip Morris Products S.A.

Terminated

Cross-Sectional Survey on the Use of Tobacco Products - Germany

Tobacco Use

Switzerland
Philip Morris Products S.A.

Completed

Nicotine Pharmacokinetics of THS Single Use of a Regular or a Menthol Stick Compared to CIG

Smoking, Tobacco

United Kingdom
Philip Morris Products S.A.

Completed

Reduced Exposure Study Using the CHTP 1.2 With 5 Days in a Confinement Setting Followed by 85 Days in an Ambulatory Setting.

Smoking

Poland
Philip Morris Products S.A.

Completed

Effect of Switching From Cigarette Smoking to IQOS on Exercise Capacity

Smoking | Exercise Capacity

Germany
Philip Morris Products S.A.

Completed

Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting Followed by 86 Days in an Ambulatory Setting

Smoking

United States
Philip Morris Products S.A.

Completed

Reduced Exposure Study in Smokers Using the Tobacco Heating System 2.2 (THS 2.2) for 5 Days in a Confinement Setting

Smoking

Japan
Philip Morris Products S.A.

Completed

Nicotine Pharmacokinetics and Pharmacodynamics, Safety and Tolerability of P3P

Pharmacokinetics

Switzerland
Philip Morris Products S.A.

Completed

Study to Investigate the Nicotine Pharmacokinetic Profiles and Pharmacodynamic Effects of P4M3 Variants

Vaping | Nicotine Absorption

United States
Philip Morris Products S.A.

Completed

Exploratory THS 2.1 Biomarkers of Exposure Study (ZRHX-EX-01)

Smoking

Poland
Philip Morris Products S.A.

Completed

Exploratory THS 2.1 Nicotine Pharmacokinetics and Safety Study

Smoking

United Kingdom
Philip Morris Products S.A.

Completed

Smoking Research Study

Smoking | Non-smoking

United Kingdom
Philip Morris Products S.A.

Completed

Nicotine Pharmacokinetics Following Use of the P4M3 Gen 2.0 E-Cigarette Compared to Smoking Cigarettes

Nicotine | Nicotine Vaping | Vaping

United States
Philip Morris Products S.A.

Terminated

Cross-Sectional Survey on the Use of Tobacco Products - London (UK)

Tobacco Use

Switzerland
Philip Morris Products S.A.

Completed

Reduced Exposure to HPHC in Smokers Switching From Cigarettes to Different Versions of THS

Smoking | Tobacco Use | Tobacco Smoking

United Kingdom
Philip Morris Products S.A.

Withdrawn

Effect of Switching From Cigarette Smoking to THS on Systemic Endothelial Function in Subjects With Established Atherosclerotic Disease

Cardiovascular Diseases | Coronary Artery Disease | Smoking | Peripheral Arterial Disease | Tobacco Use
Philip Morris Products S.A.

Completed

Reduced Exposure Study Using CHTP 1.0 During 5 Days in Confinement.

Smoking

Poland
Philip Morris Products S.A.

Completed

Effect of Switching From Cigarette Smoking to the Use of IQOS on Periodontitis Treatment Outcome

Periodontal Diseases | Gingival Diseases | Chronic Periodontitis | Smoking, Cigarette | Periodontal Pocket | Tooth Mobility

Japan
Philip Morris Products S.A.

Completed

Evaluation of Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2 for 26 Weeks

Smoking

United States
Philip Morris Products S.A.

Completed

A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2

Smoking

United States
Philip Morris Products S.A.

Completed

Prefatory Study to Explore Changes in Nasal Mucociliary Clearance and to Standardize Nasal Scraping Procedure

Smokers | Never Smokers

United States
Philip Morris Products S.A.

Completed

Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)

Smoking

United Kingdom
Philip Morris Products S.A.

Completed

Nicotine Pharmacokinetic and Pharmacodynamics Profile, Safety and Tolerability of P3L

Smoking

New Zealand
Philip Morris Products S.A.

Completed

Determination of Biomarkers of Exposure and Biomarkers of Potential Harm in Asian Adult Cigarette Smokers

Smoking | Healthy

Japan

3

Subscribe